Pancreatic cancer remains one of the most formidable challenges in modern oncology, characterized by its aggressive nature and a tendency to spread silently long before a diagnosis is made. For many patients, the very first indication of the disease is not a localized pain in the abdomen, but rather symptoms arising from secondary tumors that have already taken root in distant organs. By the time these secondary growths—known as metastases—are detected, the primary cancer has typically reached a stage where it is notoriously difficult to control, often proving resistant to the standard battery of chemotherapy and radiation.
A breakthrough study led by scientists at the University of California, San Francisco (UCSF), published on May 21 in the journal Nature, has shed new light on how these cancer cells manage to colonize such diverse environments within the human body. The research identifies a specific protein, known as PCSK9, as a critical metabolic regulator that determines whether a migrating pancreatic cancer cell will thrive in the liver or the lungs. This discovery provides a detailed look at the "biological GPS" that pancreatic cancer uses to navigate and adapt to the vastly different chemical landscapes of the body’s internal organs.
To understand the significance of this finding, one must consider the monumental task a cancer cell faces when it leaves the pancreas. For a cell, moving from the pancreas to an organ like the liver or the lung is akin to a human traveler moving between an ocean and a desert. Each environment offers entirely different resources and presents unique hazards. The liver is a metabolic powerhouse, rich in nutrients and circulating fats, while the lungs are an oxygen-dense environment that, while vital for life, can be chemically hostile to a cell not properly equipped to handle high levels of oxidative stress.
The UCSF team, led by senior author Rushika Perera, PhD, the Deborah Cowan Endowed Associate Professor of Anatomy at UCSF, sought to understand the mechanisms that allow these cells to survive such drastic transitions. The researchers began their investigation by tapping into a massive repository of genomic and behavioral data known as MetMap. Developed by the Broad Institute, an independent research organization, MetMap is a comprehensive project designed to track and map the metastatic potential of hundreds of different cancer cell lines. By analyzing this data, the UCSF researchers were able to isolate specific pancreatic cancer cell lines that exhibited a distinct preference for colonizing either the liver or the lungs.
Once these cell lines were identified, the team performed a deep genomic analysis to determine what set them apart. They were looking for a molecular signature—a difference in gene expression or protein production—that could explain why one cell line would head for the liver while another would thrive in the lungs. Their search led them to PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9). While PCSK9 is well-known in the medical community for its role in regulating blood cholesterol levels—and is the target of several modern heart disease medications—its role in the progression of pancreatic cancer had previously remained largely hidden.
The study revealed that PCSK9 acts as a metabolic switch that controls how a cancer cell acquires cholesterol, a vital building block for cell membranes and a key source of energy for rapid growth. The researchers found that when PCSK9 levels are low, pancreatic cancer cells are programmed to behave as "scavengers." In this state, they rely on taking up cholesterol from their immediate surroundings. Because the liver is a cholesterol-rich environment, these low-PCSK9 cells find it to be an ideal home, essentially feasting on the abundant resources provided by the host organ.
Conversely, when PCSK9 levels are high, the cancer cells undergo a dramatic internal shift. Instead of scavenging for cholesterol from the outside, high-PCSK9 cells begin to manufacture their own cholesterol internally. This shift to self-sufficiency is a crucial adaptation for survival in the lungs, where free-floating cholesterol is far less available than it is in the liver. However, the adaptation goes beyond just nutrient acquisition. The researchers discovered that the same metabolic pathways triggered by high levels of PCSK9 also cause the cancer cells to produce specific molecules that protect them from oxidative damage. In the oxygen-rich environment of the lungs, cells are constantly bombarded by reactive oxygen species that can tear apart cellular structures. By increasing PCSK9, the pancreatic cancer cells essentially "armor" themselves against this oxygen-induced stress, allowing them to survive in an environment that would otherwise be lethal to them.
To confirm that PCSK9 was indeed the deciding factor in where the cancer spread, the UCSF team conducted a series of sophisticated experiments in which they manipulated the protein’s expression. In one of the study’s most striking demonstrations, the researchers took cancer cells that were genetically predisposed to colonize the liver—cells with naturally low levels of PCSK9—and "forced" them to express the protein at high levels. When these modified cells were introduced, they no longer migrated to the liver. Instead, they made a biological detour, successfully colonizing the lungs. This proved that PCSK9 is not just a marker of where a cell might go, but a functional driver that dictates the cell’s destination by altering its internal chemistry to match a specific organ’s "climate."
The implications of these findings for the future of pancreatic cancer treatment are significant. Pancreatic cancer has earned a reputation for being "notoriously resistant" to many conventional therapies, in part because the cells are so adept at changing their biology to survive different stresses. By identifying PCSK9 as the master regulator of this metabolic flexibility, the UCSF study opens a new front in the effort to stop the spread of the disease. If scientists can find ways to interfere with how these cells acquire or produce cholesterol, they may be able to prevent the cells from adapting to new organs, effectively "starving" the metastasis before it can take hold.
"Cancers persist by adapting to live in new tissues and organs, and we found that pancreatic tumors use PCSK9 to adapt as they spread," said Dr. Perera. She noted that the research provides a potential roadmap for fighting metastatic growth by targeting the very pathways the cells use to survive their journey through the body. By manipulating how cells acquire their cholesterol, clinicians might one day be able to trap cancer cells in a metabolic state that makes them unable to survive outside of the primary tumor site, or at least make them more vulnerable to existing treatments.
The study also highlights the importance of collaborative, large-scale data projects like the Broad Institute’s MetMap. By providing a baseline of how different cancers behave, such resources allow researchers to move more quickly toward identifying the specific proteins and genes responsible for that behavior. This study was a multi-disciplinary effort, supported by several major scientific organizations. Funding was provided in part by the National Institutes of Health (NIH), the National Science Foundation (NSF), and the American Association for Cancer Research (AACR), reflecting the high level of priority placed on finding new avenues for pancreatic cancer intervention.
While the research is currently centered on the biological mechanisms of PCSK9 in a laboratory setting, the fact that PCSK9 inhibitors are already FDA-approved and widely used to treat high cholesterol in cardiovascular patients provides an intriguing starting point for future clinical investigations. While it is too early to say whether existing cholesterol drugs could be repurposed to treat pancreatic cancer, the UCSF study provides the essential scientific foundation needed to explore such possibilities.
As the medical community continues to grapple with the complexities of pancreatic cancer, the discovery of the PCSK9 switch represents a vital step forward. It moves the understanding of metastasis away from a model of random spread toward a more predictable model of metabolic adaptation. By viewing cancer not just as a mass of growing cells, but as a population of highly adaptable organisms that must solve specific environmental problems to survive, researchers are finding new weaknesses in an old and deadly foe. The ability to potentially "reroute" or disable the metabolic GPS of a cancer cell offers a glimmer of hope for more effective therapies in the years to come.
